Ocuphire falls as diabetes-related eye disease drug fails main study goal

Opus Genetics

26/01/2023 17:45

(Updates)
    ** Shares of eye drug developer Ocuphire Pharma Inc  OCUP.O 
fall 16.5% to $3.14
    ** Stock set for worst day since March 2022 if losses hold
    ** Company's investigational drug APX3330 for treating
diabetic retinopathy, a complication of diabetes that affects
eyes, fails to meet main goal in mid-stage study
    ** Drug demonstrated favorable safety and tolerability
profile - Ocuphire
    ** Stock up 3% in last 12 months
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com))